HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Politics Is US FDA Commissioners’ Biggest Challenge, Ex-Trump Agency Head Hahn Says

Executive Summary

In a Pink Sheet interview, Stephen Hahn also discusses the unique risk-benefit calculations that may come into play for the ‘preemptive’ therapeutics he hopes to spearhead in his new position at Flagship Pioneering and his tendency to follow in the career path of another former commissioner, Scott Gottlieb.

You may also be interested in...

Hahn Urges Fixed Terms For US FDA Leaders

Former commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH  should be selected outside the election schedule. White House task force reviewing political interference with agency science.

US FDA Finds There’s No Vaccine Against Politics

Instead of celebrating the EUA for Pfizer/BioNTech’s COVID vaccine, officials at FDA and Operation Warp Speed once again have to answer questions about President Trump’s apparent interference in the process. But while Joe Biden isn't likely to rage-tweet about the agency, the incoming administration so far hasn't shown that much respect or understanding of FDA processes either.

Time For Independent FDA? COVID-19 Political Pressure Reignites Debate

The political spotlight on the Food & Drug Administration during the COVID-19 pandemic has renewed the long-standing debate as to whether FDA should be made an independent, Cabinet-level federal agency and freed from direct HHS oversight.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts